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prehensive data on sporadic renal cell tumors are missing. 
We therefore tested a large cohort of sporadic renal tumors 
for MITF p.E318K mutation status.  Methods: Genomic DNA 
was extracted from 426 formalin-fixed, paraffin-embedded 
sporadic renal tumors that had been graded according to 
the 2004 WHO classification of renal tumors and staged ac-
cording to the 2002 TNM classification. The tumor cohort 
was enriched with papillary and chromophobe RCC, and also 
contained benign oncocytomas. DNA was tested for MITF 
p.E318K by pyrosequencing.  Results: Of 403 analyzable tu-
mors, 402 renal tumors were wild-type ones, and only 1 case 
showed the MITF p.E318K mutation. This tumor was a clear-
cell RCC (pT3b N0 M0 G3 according to the TNM classification 
2002). The affected patient was male, 61 years old, and had 
no known coexisting malignancies.  Conclusion: The MITF 
p.E318K mutation does not appear to play a major role in 
sporadic RCC carcinogenesis, but is possibly restricted to a 
rare subpopulation of inherited RCC.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Objective: The transcription factor MITF (microphthalmia-
associated transcription factor) is known to induce expres-
sion of hypoxia-inducible factor (HIF1-α), which is involved 
in renal carcinogenesis. The MITF p.E318K mutation leads to 
deficient SUMOylation of MITF, resulting in enhanced activa-
tion of its target genes. A case-control study on melanoma 
patients who coincidentally were affected by renal cell car-
cinoma (RCC) has revealed an elevated risk for mutation car-
riers to be affected by one or both of these malignancies, 
suggesting a possible role for MITF p.E318K in renal carcino-
genesis. The same study described an MITF mutation fre-
quency of 1.5% in a small cohort of sporadic RCC, but com-
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 Introduction 
 Cellular functions and intracellular communication 
are controlled and regulated both at the DNA and post-
translational levels. Posttranslational modifications (e.g. 
phosphorylation, ubiquitination, and acetylation) of
proteins are essential for triggering signal cascades and 
for maintaining fundamental developmental processes. 
Dysregulation of posttranslational modification might 
lead to dramatic malfunction of the cell, and is known 
from most malignancies. However, as recently demon-
strated, a deregulated posttranslational modification net-
work may act as a therapeutic target (e.g. in pancreatic 
cancer), and is a major focus of ongoing studies in pros-
tate cancer  [1, 2] .
 Reversible covalent conjugation of SUMO (small 
ubiquitin-related modifier) is a posttranslational modi-
fication that can modulate the function (e.g. activity,
cellular localization, and stability) of a large spectrum of 
proteins  [3] . SUMOylation frequency of a target protein 
is increased by the presence of the consensus motif ΨKXE, 
but proteins without this motif might also be prone to this 
modification  [4] . Of important functional relevance is a 
connection between the SUMOylation and ubiquitina-
tion networks, as SUMOylation can lead to ubiquitin-
dependent degradation by the proteasome  [5] . 
 The MITF (microphthalmia-associated transcription 
factor) gene encodes for a basic-helix-loop-helix leucine 
zipper transcription factor and is part of the Myc super-
gene family. The MITF gene contains two SUMOylation 
sites that can regulate SUMOylation and transcriptional 
activity of the MITF protein  [6] . 
 Recently, a germline missense mutation (p.E318K) in 
the MITF gene was described, and a predisposition to fa-
milial and sporadic melanoma in carriers of this specific 
change was documented. The affected codon is located 
within a SUMOylation consensus motif, and the muta-
tion interferes with MITF SUMOylation. In vitro studies 
revealed both enhanced binding of mutated MITF to the 
promoter of the hypoxia-inducible factor (HIF1-α) gene, 
which is a target gene of the MITF transcription factor, 
and increased activity of the HIF1-α promoter caused by 
this binding  [7, 8] . Increased expression of HIF1-α is cor-
related with the development of clear-cell renal cell carci-
nomas (RCC), and overexpression of HIF1-α has been 
found in most clear-cell RCC cases analyzed to date  [9] . 
Most interesting, a significantly increased frequency of 
RCC compared to normal controls was detected in mela-
noma patients with the p.E318K germline mutation in 
MITF  [7, 10] . These findings suggest MITF as a possible 
connection point between melanoma and RCC. In addi-
tion, mutation analysis of a small cohort of sporadic RCC
cases showed a MITF p.E318K mutation frequency of 
1.5%  [7] . Currently, the role of the MITF mutation in 
RCC development remains unclear, as comprehensive 
mutation data from sporadic RCC cases are missing. 
Therefore, the aim of our study was to screen a large co-
hort of Caucasian sporadic renal tumor cases for the 
MITF p.E318K mutation.
 Materials and Methods 
 Patients and Tissue Samples 
 Overall, 426 formalin-fixed, paraffin-embedded archival spo-
radic renal tumors were used for the study. The cases were classi-
fied according to the 2004 WHO classification of renal tumors and 
staged according to the 2002 TNM classification  [11, 12] . Charac-
teristics of the study cohort are shown in  table 1 . Prior institution-
al review board approval (University Hospital Erlangen, Germa-
ny) was obtained for the study.
 Table 1.  Patient and tumor characteristics (n = 426)
Gender, n
Male 217
Female 131
Unknown 78
Age, years
Range 19 – 91
Median 65
Mean 63.04
Tumor type, n
Clear-cell RCC 175
Papillary RCC 77
Chromophobe RCC 97
Renal oncocytoma 58
Others 19
2002 TNM classification, n
pT1a 129
pT1b 80
pT2 58
pT3a 41
pT3b 31
Unknown 29
2002 TNM stage, n
Stage I 160
Stage II 32
Stage III 47
Stage IV 21
Unknown 108
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 Tissue Microdissection and DNA Isolation 
 DNA was extracted from renal tumor samples from serial sec-
tions after manual microdissection as described previously  [13] . 
In brief, 5-μm-thick serial sections of the tumor tissue were de-
waxed and stained with 0.1% methylene blue for 15 s. Using an 
inverted microscope, the tumor tissue (identified through match-
ing with a marked hematoxylin and eosin-stained section re-
viewed by an experienced surgical pathologist) was scraped off 
with a sterile needle to obtain a purity of the cells of at least 85%. 
Isolation of genomic DNA of the microdissected tumor tissue was 
performed using the High Pure PCR Template Preparation Kit 
(Roche, Mannheim, Germany) according to the manufacturer’s 
instructions.
 Sequence Analysis of Codon 318 of MITF 
 For mutation analysis, the hot spot region of the MITF gene 
containing codon 318 was amplified using the multiplex PCR-kit 
according to manufacturer’s instructions (Qiagen, Hilden, Ger-
many) and the following primers: forward: 5 ′ -TTATTCCATC-
CACGGGTCTC-3 ′ , and reverse: 5 ′ -biotin GAGGTCTTGGCTG-
CAGTTCT-3 ′ . The cycling conditions were as follows: a single 
cycle of denaturation at 94   °   C for 5 min, 45 cycles at 94   °   C for 1 
min, 58.3   °   C for 1 min, and 72   °   C for 1 min, and a final 10-min
extension at 72   °   C. For pyrosequencing (PyroMark Q24; Qiagen) 
single-stranded DNA was prepared from 25 ml of biotinylated 
PCR product with streptavidin-coated sepharose and 0.5 m M of 
the sequencing primer 5 ′ -AATCGGATCATCAAGC-3 ′ using
the PSQ Vacuum Prep Tool (Qiagen). Pyrosequencing assay setup 
was selected in ‘Sequence to Analyze’ with the sequence AAG/A 
AAC CCG TT. The following dispensation order was used: GAA 
GAC GT.
 Results 
 Sequencing data were available from 403/426 (94.6%) 
cases. In 23 cases, no PCR products were obtained due to 
strong fragmentation of the DNA after formalin fixation. 
Of the 403 analyzable cases, 402 (99.8%) showed wild-
type MITF p.E318. Only 1 (0.2%) case showed the MITF 
p.E318K mutation ( fig. 1 ). This case was a clear-cell RCC 
(pT3b N0 M0 G3 according to the TNM classification 
2002). The affected patient was male, 61 years old, and 
had no known coexisting malignancies.
 Discussion  
 In this study we analyzed the p.E318K mutation of 
MITF in a large cohort of sporadic renal cell tumors. 
Only one of the cases investigated showed the mutation 
known as a germline alteration from patients with famil-
ial melanoma and/or RCC. The resulting allele frequency 
of the mutation in our cohort was 0.12%. The low fre-
quency detected might hint to technical problems or 
contaminated material, but positive and negative con-
trols showed the expected results. Moreover, this muta-
tion frequency was comparable to those of the general 
populations of France (frequency = 0.3%), Australia (fre-
quency = 0.72%), Poland (0.09%), and the UK (frequen-
cy = 0.85%)  [8, 14, 15] . Furthermore, Guo et al.  [16] per-
formed exome sequencing on 10 clear-cell RCC and 
screened >1,000 genes (including MITF) in an addition-
al 88 clear-cell RCC cases, but could not detect an MITF 
mutation. Furthermore, the TCGA Research Network 
published an extensive molecular profiling of 417 clear-
cell RCC samples. Overall, MITF alterations were report-
ed in 2.6% of the cases with 9/11 mutated tumors show-
ing deep deletions and only 2/11 mutated tumors dis-
playing point mutations (p.T110M, p.G165D). The 
p.E318K mutation could not be detected at all  [17] . 
Through cBioPortal  [18, 19] , provisional sequencing 
data from an additional 161 papillary RCC cases ana-
lyzed by the TCGA Research Network are available. In 
this cohort, 3/161 (2.6%) cases showed truncating (p.
K118 * , p.K198fs) or missense (p.A205V) mutations 
within the MITF gene. Again, the p.E318K mutation al-
lele was not found. Thus, combining all available data, 
the overall MITF mutation frequency is approximately 
1.4% (15/1,079 cases with mutation). 
 Altogether, these data support our results on MITF 
p.E318K frequency in sporadic RCC and therefore argue 
for their validity. In conclusion, the MITF p.E318K muta-
tion only plays a minor role in the development of spo-
radic RCC.
 Despite the rarity of MITF mutations, they might trig-
ger RCC development in specific cases, as mutated MITF 
displays enhanced binding to the HIF1-α promoter and 
has been shown to increase HIF1-α promoter activity. 
Moreover, MITF also acts as a transcription factor and is 
able to directly control MET transcription  [20] . Activat-
ing mutations in the MET proto-oncogene are especially 
frequent in papillary type 1 RCC (about 15%)  [21] . These 
mutations lead to activation of several pathways resulting 
in, for example, tumor cell proliferation, invasion, and 
angiogenesis. Mutations in MITF interrupting its con-
trolled degradation might constantly increase MET tran-
scription and result in similar effects as mutational MET 
activation. It is conceivable that this effect, in combina-
tion with additional harmful events, makes a cell prone to 
malignant transformation. This is supported by the re-
cent description of an actin gamma 1 (ACTG1)-MITF fu-
sion in a case of papillary RCC  [22] . In vitro studies of this 
fusion protein revealed an induction of, for example, 
HIF1-α and MET transcription in HEK293T cells, and an 
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increased colony-forming ability in NIH3T3 cells. These 
data gave the first evidence for a similar tumorigenic po-
tential of MITF fusion proteins as is attributed to TFE3 
fusions.
 In summary, the MITF p.E318K mutation does not 
seem to play a major role in sporadic RCC development 
in Caucasians, but is possibly restricted to a rare subpop-
ulation of inherited RCC. Nonetheless, in general, MITF 
alterations might contribute to the development of spo-
radic RCC as they affect targets already known to be in-
volved in RCC pathobiology.
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 Fig. 1. Representative examples for pyro-
sequencing analysis (pyrogram) of codon 
318 (5 ′ -GAA-3 ′ ) of the MITF gene.  a RCC 
showing a wild-type sequence.  b Positive 
control for the MITF p.E318K (5 ′ -GAA-3 ′ 
 → 5 ′ - A AA-3 ′ ) mutation from a melanoma 
case with the germline mutation. The 
downward-pointing arrow indicates the 
reduction of the wild-type ‘G’ signal and 
the increase in the mutant ‘A’ signal. The 
‘G’-to-‘A’ mutation led to a stretch of 5× ‘A’ 
in a row interrupted by the ‘G’ signal 
(downward-pointing arrow) from the 
wild-type background.  c Clear-cell RCC 
with the MITF p.E318K mutation. The py-
rogram is identical to that of the positive 
control.  d Negative control (H 2 O). 
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